...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas
【24h】

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

机译:结合靶向核输出和RNA翻译抑制侵袭性B细胞淋巴瘤

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aggressive double-and triple-hit (DH/TH) diffuse large B-cell lymphomas (DLBCLs) feature activation of Hsp90 stress pathways. Herein, we show that Hsp90 controls posttranscriptional dynamics of key messenger RNA(mRNA) species including those encoding BCL6, MYC, and BCL2. Using a proteomics approach, we found that Hsp90 binds to and maintains activity of eIF4E. eIF4E drives nuclear export and translation of BCL6, MYC, and BCL2 mRNA. eIF4E RNA-immunoprecipitation sequencing in DLBCL suggests that nuclear eIF4E controls an extended program that includes B-cell receptor signaling, cellular metabolism, and epigenetic regulation. Accordingly, eIF4E was required for survival of DLBCL including the most aggressive subtypes, DH/TH lymphomas. Indeed, eIF4E inhibition induces tumor regression in cell line and patient-derived tumorgrafts of TH-DLBCL, even in the presence of elevated Hsp90 activity. Targeting Hsp90 is typically limited by counter-regulatory elevation of Hsp70B, which induces resistance to Hsp90 inhibitors. Surprisingly, we identify Hsp70 mRNA as an eIF4E target. In this way, eIF4E inhibition can overcome drug resistance to Hsp90 inhibitors. Accordingly, rational combinatorial inhibition of eIF4E and Hsp90 inhibitors resulted in cooperative antilymphoma activity in DH/TH DLBCL in vitro and in vivo.
机译:侵袭性的双重和三次打击(DH / TH)弥漫性大B细胞淋巴瘤(DLBCL)的特点是Hsp90应激途径的激活。在这里,我们显示Hsp90控制关键信使RNA(mRNA)物种(包括那些编码BCL6,MYC和BCL2的物种)的转录后动力学。使用蛋白质组学方法,我们发现Hsp90结合并维持eIF4E的活性。 eIF4E驱动核输出以及BCL6,MYC和BCL2 mRNA的翻译。 DLBCL中的eIF4E RNA免疫沉淀测序表明,核eIF4E控制着扩展程序,包括B细胞受体信号转导,细胞代谢和表观遗传调控。因此,eIF4E是包括最积极的亚型DH / TH淋巴瘤在内的DLBCL生存所必需的。实际上,即使在Hsp90活性升高的情况下,eIF4E抑制作用也会在TH-DLBCL细胞系和患者来源的肿瘤移植物中诱导肿瘤消退。靶向Hsp90通常受到Hsp70B的反调控升高的限制,这会引起对Hsp90抑制剂的抗性。令人惊讶的是,我们确定Hsp70 mRNA作为eIF4E的目标。以这种方式,eIF4E抑制可以克服对Hsp90抑制剂的耐药性。因此,在体外和体内,对eIF4E和Hsp90抑制剂的合理组合抑制导致DH / TH DLBCL中协同的抗淋巴瘤活性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号